Affiliation: King's College London
- Addiction and the pharmacology of cannabis: implications for medicine and the lawMalcolm Lader
Institute of Psychiatry King s College, Denmark Hill, London SE5 8AF
Med Sci Law 49:1-17. 2009..Suggestions are made for further research into the pharmacology and toxicology of CBD. Such data may also point to a more rational evidence-based approach to the legal control of cannabis preparations...
- Pharmacotherapy of mood disorders and treatment discontinuationMalcolm Lader
Institute of Psychiatry, King s College London, London, UK
Drugs 67:1657-63. 2007..To this end, physicians should educate themselves and the public about discontinuation and withdrawal, so that these clinical features can be put in a realistic context...
- The effect of escitalopram on sleep problems in depressed patientsM Lader
Institute of Psychiatry, University of London, London, UK
Hum Psychopharmacol 20:349-54. 2005..A further prospective study is needed to establish this useful clinical effect in insomniac depressives...
- Management of panic disorderMalcolm Lader
Institute of Psychiatry, Denmark Hill, London, SE5 8AF, UK
Expert Rev Neurother 5:259-66. 2005..Cognitive behavioral therapy is the psychologic treatment of first choice. The methods of combining drug and nondrug treatments need careful and thorough exploration...
- A NICE missed opportunity?Malcolm Lader
Institute of Psychiatry, King's College London, De Crespigny Park, London, UK
J Psychopharmacol 19:136-8. 2005
- Antiparkinsonian medication and pathological gamblingMalcolm Lader
Institute of Psychiatry, King s College, London, England
CNS Drugs 22:407-16. 2008..The mechanism of this adverse effect is believed to be excessive dopaminergic stimulation but probably not specifically involving D3 receptors. A parallel to addictive behaviour with stimulant drugs has been noted...
- Effectiveness of benzodiazepines: do they work or not?Malcolm Lader
P056, Institute of Psychiatry, King s College, London, Denmark Hill, London, SE5 8AF, UK
Expert Rev Neurother 8:1189-91. 2008..I point out the changes in diagnostic criteria over the years and the lack of accepted methods of assessing estimates of effectiveness in clinical practice. Excessive prescribing of these controversial drugs is likely to continue...
- Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose studyMalcolm Lader
Institute of Psychiatry, University of London, London, SE5 8AF, UK
Depress Anxiety 19:241-8. 2004..It is concluded that doses of 5-20 mg escitalopram are effective and well tolerated in the short- and long-term treatment of generalised SAD...
- Withdrawing benzodiazepines in primary careMalcolm Lader
Institute of Psychiatry, King s College London, London, England
CNS Drugs 23:19-34. 2009..Some of the principles of withdrawing benzodiazepines are listed. Antidepressants may be helpful, as may some symptomatic remedies. Care must be taken not to substitute one drug dependence problem for the original one...
- Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic targetMalcolm Lader
PO Box 56, Institute of Psychiatry, Denmark Hill, London SE5 8AF, United Kingdom
Eur Neuropsychopharmacol 17:743-55. 2007..Disturbances in circadian rhythms may be an integral part of depressive mechanisms, and normalising them via an innovative mechanism of antidepressant action may be a fruitful avenue in the search for improved antidepressant agents...
- A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorderM Lader
Institute of Psychiatry, London, UK
Psychopharmacology (Berl) 139:402-6. 1998..75 versus 7.23 points, respectively). Secondary variables such as CGI and self-ratings (HAD scale) showed both hydroxyzine and buspirone to be more efficacious than placebo. Thus, hydroxyzine is a useful treatment for GAD...
- Classification and drug treatment of the anxiety disordersMalcolm Lader
Institute of Psychiatry, King's College London, UK
Seishin Shinkeigaku Zasshi 106:1242-53. 2004
- Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensionsDan J Stein
University of Cape Town, South Africa and University of Florida, Gainesville, USA
Eur Neuropsychopharmacol 16:33-8. 2006..This paper examines data from a fixed-dose trial of escitalopram versus paroxetine, in order to determine the differential effects of these agents on symptom dimensions in social anxiety disorder (SAD)...
- Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensionsDan J Stein
MRC Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa
Depress Anxiety 20:175-81. 2004..A six-factor model of social anxiety symptoms is supported by the distinctive association between these symptom dimensions and different areas of disability, but did not predict differential response to escitalopram...
- Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorderPaolo Meoni
Wyeth Research, Paris, France
Depress Anxiety 19:127-32. 2004....
- Discontinuation symptoms in depression and anxiety disordersDavid S Baldwin
Clinical Neurosciences Division, School of Medicine, University of Southampton, UK
Int J Neuropsychopharmacol 10:73-84. 2007..Thus, discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders. No evidence was seen for a higher discontinuation burden with longer treatment...
- Mortality in schizophreniaPascal Auquier
Departement de sante publique, Faculte de Medecine, La Timone, Marseille, France
Pharmacoepidemiol Drug Saf 15:873-9. 2006..The purpose of this article is to describe the current status of knowledge on excess mortality in schizophrenia and its causative factors, and to expand upon previous work evaluating approaches that may reduce mortality rates...
- Which antidepressants have demonstrated superior efficacy? A review of the evidenceStuart A Montgomery
Imperial College School of Medicine, University of London, UK
Int Clin Psychopharmacol 22:323-9. 2007..This review of published data found evidence that only a very few antidepressants are shown to be more effective than others...
- Mortality in schizophreniaPascal Auquier
Servíce Santé Publique, Faculte de Medecine, France
Pharmacoepidemiol Drug Saf 16:1308-12. 2007..Careful selection of antipsychotic drugs, some of which are associated with side effects such as weight gain and cardiac disorders, will also help reduce co-morbidity and mortality among patients with schizophrenia...